X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multicenter phase-ii (1035) 1035
humans (768) 768
oncology (691) 691
index medicus (573) 573
chemotherapy (408) 408
female (351) 351
aged (285) 285
cancer (284) 284
middle aged (271) 271
antineoplastic combined chemotherapy protocols - therapeutic use (247) 247
male (242) 242
adult (220) 220
treatment outcome (207) 207
antineoplastic agents - therapeutic use (200) 200
trial (192) 192
therapy (154) 154
care and treatment (150) 150
pharmacology & pharmacy (147) 147
hematology (140) 140
deoxycytidine - analogs & derivatives (123) 123
non-hodgkins-lymphoma (121) 121
animals (119) 119
breast neoplasms - drug therapy (113) 113
capecitabine (113) 113
1st-line treatment (112) 112
metastasis (112) 112
cisplatin (109) 109
prognosis (100) 100
rituximab (97) 97
aged, 80 and over (95) 95
clinical trials as topic (95) 95
research (93) 93
breast cancer (92) 92
antineoplastic combined chemotherapy protocols - adverse effects (91) 91
medicine & public health (91) 91
open-label (91) 91
hematology, oncology and palliative medicine (90) 90
deoxycytidine - administration & dosage (89) 89
tumors (89) 89
retrospective studies (88) 88
combination (87) 87
growth-factor receptor (82) 82
health aspects (82) 82
drug therapy (81) 81
antibodies, monoclonal - therapeutic use (80) 80
gemcitabine (80) 80
paclitaxel (79) 79
neoplasm staging (78) 78
oxaliplatin (78) 78
neoplasm metastasis (76) 76
disease-free survival (73) 73
lymphomas (73) 73
fluorouracil - analogs & derivatives (72) 72
survival analysis (72) 72
antineoplastic agents - pharmacology (71) 71
cell lung-cancer (70) 70
fluorouracil - administration & dosage (70) 70
breast neoplasms - pathology (69) 69
survival rate (69) 69
antineoplastic combined chemotherapy protocols - administration & dosage (68) 68
clinical trials (68) 68
combined modality therapy (66) 66
radiotherapy (66) 66
5-fluorouracil (65) 65
antineoplastic agents (63) 63
docetaxel (63) 63
cetuximab (62) 62
drug administration schedule (61) 61
randomized-trial (61) 61
review (61) 61
stomach neoplasms - drug therapy (61) 61
analysis (60) 60
efficacy (60) 60
lymphoma (60) 60
lung neoplasms - drug therapy (59) 59
anti-cd20 monoclonal-antibody (57) 57
antineoplastic agents - adverse effects (57) 57
disease progression (57) 57
survival (57) 57
gastric cancer (56) 56
antimitotic agents (55) 55
colorectal cancer (55) 55
irinotecan (55) 55
cancer therapies (54) 54
fluorouracil (54) 54
surgery (54) 54
targeted therapy (54) 54
drug resistance, neoplasm (53) 53
tyrosine kinase inhibitor (53) 53
immunotherapy (52) 52
antineoplastic agents - administration & dosage (51) 51
breast-cancer (51) 51
chronic lymphocytic-leukemia (50) 50
molecular targeted therapy (49) 49
article (47) 47
carcinoma (47) 47
patients (47) 47
colorectal neoplasms - drug therapy (46) 46
metastatic colorectal-cancer (46) 46
organoplatinum compounds - administration & dosage (46) 46
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 01/2018, Volume 62, pp. 110 - 122
Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer which lacks oestrogen receptors, progesterone receptors and HER2... 
Biomarkers | Combination therapy | Targeted therapy | Triple-negative breast cancer | CLINICAL-TRIAL | MULTICENTER PHASE-II | TUMOR-INFILTRATING LYMPHOCYTES | GROWTH-FACTOR RECEPTOR | SINGLE-AGENT | MEK INHIBITOR | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | DOUBLE-BLIND | SODIUM-CHANNEL EXPRESSION | PARP INHIBITORS
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 06/2018, Volume 61, Issue 12, pp. 5162 - 5186
We pursued a structure-guided approach toward the development of improved dihydroorotate dehydrogenase (DHODH) inhibitors with the goal of forming new... 
TRIAL | POTENT | CHEMISTRY, MEDICINAL | MULTICENTER PHASE-II | DUP-785 | ANTICANCER AGENT | OPTIMIZATION | BREQUINAR SODIUM | PYRIMIDINE SYNTHESIS | CANCER | LEFLUNOMIDE
Journal Article
Journal Article
Chemical Society Reviews, ISSN 0306-0012, 10/2015, Volume 44, Issue 21, pp. 7737 - 7763
Numerous variations on structural motifs exist within pharmaceutical compounds that have entered the clinic. These variations have amounted over many decades... 
PEPTIDASE-IV INHIBITOR | EVERY 3 WEEKS | PROTEIN-KINASE-C | MULTICENTER PHASE-II | DRUG DISCOVERY | 1ST TOTAL-SYNTHESIS | DOUBLE-BLIND | TOPICAL TREATMENT | INGENOL MEBUTATE GEL | CHEMISTRY, MULTIDISCIPLINARY | POSTOPERATIVE PAIN | Drugs | Structural members | Natural products | Hydrocarbons | Biology | Carbon | Three dimensional | Pharmaceuticals
Journal Article
NATURE REVIEWS DRUG DISCOVERY, ISSN 1474-1776, 02/2007, Volume 6, Issue 2, pp. 115 - 120
Thirty-five years after the 'war on cancer' was declared, the discovery of anticancer drugs remains a highly challenging endeavour. Here, we consider the... 
GROWTH-FACTOR RECEPTOR | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | MULTICENTER PHASE-II | CLINICAL-TRIALS | IMATINIB | RESISTANCE | SMALL-CELL LUNG | PHARMACOLOGY & PHARMACY | KINASE INHIBITORS | MUTATIONS | POSITIVE LEUKEMIAS | EXPRESSION
Journal Article